Exploring Tetrazolium Salt Reduction by Mono- and Bimetallic Nanoparticles as an Alternative Signal-Generation Strategy for Point-of-Care Diagnostics
Biosensors · 29.06.2026 · 16 (7) · 360
DOI: 10.3390/bios16070360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors, online erschienen am 29.06.2026. Verfasst von Paweł Stańczak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Diagnostics, Centre for Advanced Materials and Technologies CEZAMAT, Poleczki 19, 02-822 Warsaw, Poland. Hauptthemen laut MEDLINE: Metal Nanoparticles, Point-of-Care Systems, Tetrazolium Salts, Biosensing Techniques. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Warsaw University of Technology.
Abstract (Originalsprache)
Nanozymes, nanomaterials that mimic enzymatic activity, offer superior stability, tunability, and lower production costs compared to natural enzymes. To date, most nanozyme-based point-of-care (PoC) diagnostic systems have relied on oxidation reactions, such as oxidation of 3,3′,5,5′-tetramethylbenzidine, which often suffer from limited substrate stability and high background signal. This study investigates reduction reactions, particularly those involving tetrazolium salts, as an alternative route for signal generation in PoC devices. For this purpose, monometallic and bimetallic gold, palladium, and platinum nanoparticles were synthesized via chemical reduction using poly(vinyl alcohol) as a stabilizing agent. The resulting nanoparticles were uniform in size and morphology. Their catalytic performance was confirmed through the reduction of 4-nitrophenol. The tetrazole salts were selected as promising substrates for application in PoC settings and further explored by examining the nanozyme-based reduction of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT). The nanozymes catalyzed the reduction of MTT in the presence of sodium borohydride, producing a distinct colorimetric signal under selected conditions. The effects of reducing agent concentration, buffer pH, and potential interferents were evaluated, with performance suitable for PoC devices achieved at basic pH and low borohydride concentration. Interference studies showed negligible MTT reduction in the presence of physiological levels of ascorbic acid, human serum albumin, and 10% concentration of human serum. Finally, a proof-of-concept lateral flow assay demonstrated successful signal generation through nanozyme-catalyzed MTT reduction. Results establish tetrazolium salts as suitable substrates for nanozyme-enhanced PoC diagnostics and highlight reduction-based chromogenic systems as a viable alternative to traditional oxidation-based assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Diagnostics, Centre for Advanced Materials and Technologies CEZAMAT, Poleczki 19, 02-822 Warsaw, Poland.
- Chair of Medical Biotechnology, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warsaw, Poland.
ORCID-Profile: Maciej Trzaskowski, Mariusz Pietrzak
Förderung
- Warsaw University of Technology
Zitieren
APA
Stańczak, P., Trzaskowski, M., & Pietrzak, M. (2026). Exploring Tetrazolium Salt Reduction by Mono- and Bimetallic Nanoparticles as an Alternative Signal-Generation Strategy for Point-of-Care Diagnostics. Biosensors, 16(7), 360. https://doi.org/10.3390/bios16070360
Vancouver
Stańczak P, Trzaskowski M, Pietrzak M. Exploring Tetrazolium Salt Reduction by Mono- and Bimetallic Nanoparticles as an Alternative Signal-Generation Strategy for Point-of-Care Diagnostics. Biosensors. 2026;16(7):360. doi:10.3390/bios16070360
BibTeX
@article{Staczak2026,
author = {Stańczak, Paweł and Trzaskowski, Maciej and Pietrzak, Mariusz},
title = {Exploring Tetrazolium Salt Reduction by Mono- and Bimetallic Nanoparticles as an Alternative Signal-Generation Strategy for Point-of-Care Diagnostics},
journal = {Biosensors},
year = {2026},
volume = {16},
number = {7},
pages = {360},
doi = {10.3390/bios16070360}
}
EUVIMED